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OBJECTIVES: Estimate the cost of an asthma exacerba-
tion and its management in the hospital setting in Spain.
METHODS: Prospective observational study conducted
in six Spanish hospitals during 2000 on 126 patients suf-
fering an asthma exacerbation, who were treated rou-
tinely. Both direct and indirect costs of each episode were
calculated. RESULTS: Forty-two (33.3%) of the exacer-
bations were mild, 49 (38.9%) moderate, 33 (26.2%)
severe and 2 (1.6%) had risk of imminent respiratory
arrest (IRA). Twenty-four percent of the severe exacer-
bations occurred in patients with a diagnosis of intermit-
tent mild asthma. The most frequently prescribed drugs
to treat exacerbations were oral corticosteroids and short-
acting beta-2-agonists and those most frequently used
before the exacerbation were short-acting beta-2-agonists
and inhaled corticosteroids. An average of 8.1 diagnostic
tests were conducted to resolve an exacerbation. The
average cost of an attack was €1555.7 (CI 95%
1237.6–1907). Costs increased with the severity of the
attack, the cost of a mild attack being €292.6 (CI 95%
176–452.4), moderate €1230.5, (CI 95% 860.6–1605.8),
and severe €3543.1, (CI 95% 2908.7–4191.3). The cost
of an IRA episode was less than that of a severe attack:
€3255.7 (CI 95% 1188.2–5323.2). Direct costs repre-
sented 93.9% of the total cost (indirect costs 6.11%);
costs arising from hospitalisation, transport, and re-
admission accounted for 82.6% and medication 5.9% of
the direct costs. CONCLUSIONS: Although the drugs
used for both management and prevention of asthma
exacerbations are correct, the fact that moderate and/or
severe exacerbations are a majority suggests that either
preventive treatment was inadequate for the degree of
asthma prior to the exacerbation or there was non-
adherence to treatment. The cost of an asthma attack
treated in the hospital setting is high, (€1555.7 CI 95%
1237.6–1907), largely due to hospitalisation, transport,
and readmission costs.
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OBJECTIVE: Resource utilisation by asthma patients is
greater than non-asthmatic patients and increases with
disease severity, but little information exists on asthma
costs by control status of the disease. The objective is to
estimate the costs associated with controlled and poorly
controlled moderate to severe asthma patients in the UK.
METHODS: A cross-sectional, observational study was
performed in three UK sites to capture resource use by
the deﬁned population. Data on demographics, clinical
history, disease characteristics, and direct Health care
resource utilisation was captured retrospectively over a 1-
year period. Prospective health resource utilisation data
were collected over 4 weeks, including productivity losses
for patient or caregiver, using patient diaries. All relevant
variables were summarised and analysed using descriptive
statistics by entire population and grouped by severity
with poorly controlled deﬁned as oral steroid use and
unscheduled GP/emergency visit or a hospital admission
for asthma in the preceding year. RESULTS: There were
274 retrospective patients: 214 were controlled and 60
were poorly controlled with annual average direct
medical costs of £369 (95% CI: £259–£517) and £873
(95% CI: £492–£1392), respectively. Prospective data
were collected on 80 patients: 72 controlled and 8 poorly
controlled. Monthly average costs per patient in the con-
trolled group were £176 (95% CI: £87–£297), of which
£64 (95% CI: £19–£116) were indirect costs. In the
poorly controlled group, monthly average costs per
patient were £2,731 (95% CI: £1242–£4735) of which
£998 (95% CI: £395–£1663) were indirect costs. CON-
CLUSIONS: Although the poorly controlled groups were
small, results suggest that improving asthma control in
those poorly controlled will decrease health care and soci-
etal costs as well as patient morbidity.
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OBJECTIVE: to compare costs and effects of salme-
terol/ﬂuticasone propionate combination (SFC) 50/250mg
bd with formoterol (12mg bd) and budesonide (800mg
